Alfons Navarro

6.0k total citations · 1 hit paper
102 papers, 4.0k citations indexed

About

Alfons Navarro is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Alfons Navarro has authored 102 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Molecular Biology, 53 papers in Cancer Research and 20 papers in Oncology. Recurrent topics in Alfons Navarro's work include Cancer-related molecular mechanisms research (40 papers), MicroRNA in disease regulation (35 papers) and Circular RNAs in diseases (24 papers). Alfons Navarro is often cited by papers focused on Cancer-related molecular mechanisms research (40 papers), MicroRNA in disease regulation (35 papers) and Circular RNAs in diseases (24 papers). Alfons Navarro collaborates with scholars based in Spain, United States and China. Alfons Navarro's co-authors include Mariano Monzó, Jesús García‐Foncillas, Tania Díaz, Eva Bandrés, Bernat Gel, Núria Viñolas, Ramón M. Marrades, I. Moreno, Ruth Zárate and Natalia Ramírez and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Alfons Navarro

101 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.

2006 706 citations Eva Bandrés, Elena Cubedo et al. Molecular Cancer profile →

Peers

Countries citing papers authored by Alfons Navarro

Since Specialization

Citations

This map shows the geographic impact of Alfons Navarro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfons Navarro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfons Navarro more than expected).

Fields of papers citing papers by Alfons Navarro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfons Navarro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfons Navarro. The network helps show where Alfons Navarro may publish in the future.

Co-authorship network of co-authors of Alfons Navarro

This figure shows the co-authorship network connecting the top 25 collaborators of Alfons Navarro. A scholar is included among the top collaborators of Alfons Navarro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfons Navarro. Alfons Navarro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer: Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients 2025 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Laureano Molins, David Sánchez-Lorente, Daniel Martı́nez, Tania Díaz, Risha Na, Ramón M. Marrades, Alfons Navarro	0
2	A signature of five 7-methylguanosine-related genes is a prognostic marker for lung squamous cell carcinoma 2023 ·Journal of Thoracic Disease ·Wensheng Liu, Ying Wang, Paola Ulivi, Simona Tavolari, Syed A. A. Rizvi, Enrico Capobianco, Alfons Navarro, Yongjun Zhang	3
3	Screening for Prognostic microRNAs Associated with Treatment Failure in Diffuse Large B Cell Lymphoma 2022 ·Cancers ·Leyre Bento, Oliver Vögler, (unknown), Josep Muncunill, (unknown), (unknown), (unknown), Rafael Ramos, Víctor J. Asensio, Concepción Fernández‐Rodríguez, Antonio Salar, Alfons Navarro, Raquel Del Campo, (unknown), Regina Alemany, Antonio Gutiérrez	9
4	Human embryonic mesenchymal lung-conditioned medium promotes differentiation to myofibroblast and loss of stemness phenotype in lung adenocarcinoma cell lines 2022 ·Journal of Experimental & Clinical Cancer Research ·(unknown), Alfons Navarro, (unknown), Josep M. Canals, Tania Díaz, (unknown), (unknown), Bing Han, (unknown), Mariano Monzó	4
5	LncRNA Quantification from Extracellular Vesicles Isolated from Blood Plasma or Conditioned Media 2021 ·Methods in molecular biology ·Joan J. Castellano, (unknown), Bing Han, Tania Díaz, Mariano Monzó, Alfons Navarro	6
6	LincRNA-p21 Levels Relates to Survival and Post-Operative Radiotherapy Benefit in Rectal Cancer Patients 2020 ·Life ·(unknown), Joan J. Castellano, Isabel Moreno, F Martínez-Ródenas, Raquel Hernández, (unknown), Tania Díaz, Bing Han, Carmen Muñoz, Albert Biete, Mariano Monzó, Alfons Navarro	8
7	Extracellular Vesicle lincRNA-p21 Expression in Tumor-Draining Pulmonary Vein Defines Prognosis in NSCLC and Modulates Endothelial Cell Behavior 2020 ·Cancers ·Joan J. Castellano, Ramón M. Marrades, Laureano Molins, Núria Viñolas, Jorge Moisés, (unknown), Bing Han, Yan Li, Daniel Martı́nez, Mariano Monzó, Alfons Navarro	41
8	Twist1 activated circRNA-10720 is a new player in hepatocellular carcinoma metastasis 2019 ·Translational Cancer Research ·Alfons Navarro	1
9	Proteomic Analysis of Liquid Biopsy from Tumor-Draining Vein Indicates that High Expression of Exosomal ECM1 Is Associated with Relapse in Stage I-III Colon Cancer 2018 ·Translational Oncology ·Sandra Santasusagna, Isabel Moreno, Alfons Navarro, Joan J. Castellano, (unknown), Raquel Hernández, Carmen Muñoz, Mariano Monzó	20
10	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia 2018 ·Leukemia & lymphoma ·Montserrat Torrebadell, Marina Díaz‐Beyá, Susana G. Kalko, Marta Pratcorona, Josep Nomdedéu, Alfons Navarro, Bernat Gel, Salut Brunet, Jorge Sierra, Mireia Camós, Jordi Esteve	16
11	MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia 2013 ·Leukemia ·Marina Díaz‐Beyá, Salut Brunet, Josep Nomdedéu, Rut Tejero, Tania Díaz, Marta Pratcorona, Mar Tormo, Josep‐María Ribera, Lourdes Escoda, Rafael F. Duarte, David Gallardo, Inmaculada Heras, Maria Paz Queipo De Llano, Joan Bargay, Mariano Monzó, Jorge Sierra, Alfons Navarro, Jordi Esteve, (unknown)	47
12	Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer 2012 ·European Respiratory Journal ·Marc Campayo, Alfons Navarro, Núria Viñolas, Tania Díaz, Rut Tejero, Josep María Gimferrer, Laureano Molins, María Luisa Cabañas, José Ramírez, Mariano Monzó, Ramón M. Marrades	64
13	Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis 2011 ·PLoS ONE ·Tania Díaz, Alfons Navarro, Gerardo Ferrer, Bernat Gel, Anna Gayà, Rosa Artells, Beatríz Bellosillo, M. García García, Sergi Serrano, Antonio Martı́nez, Mariano Monzó	62
14	Single Nucleotide Polymorphisms in Tobacco Metabolism and DNA Repair Genes and Prognosis in Resected Non-Small-Cell Lung Cancer 2011 ·Journal of Surgical Research ·Marc Campayo, Núria Viñolas, Alfons Navarro, Enric Carcereny, Francesc Casas, Bernat Gel, Tania Díaz, Josep María Gimferrer, Ramón M. Marrades, José Ramírez, Mariano Monzó	6
15	A Dual Role for KRT81: A miR-SNP Associated with Recurrence in Non-Small-Cell Lung Cancer and a Novel Marker of Squamous Cell Lung Carcinoma 2011 ·PLoS ONE ·Marc Campayo, Alfons Navarro, Núria Viñolas, Rut Tejero, Carmen Muñoz, Tania Díaz, Ramón M. Marrades, María Luisa Cabañas, Josep María Gimferrer, Pere Gascón, José Ramírez, Mariano Monzó	50
16	Hematopoiesis-related microRNA expression in myelodysplastic syndromes 2009 ·Leukemia & lymphoma ·Aina Pons, Benet Nomdedeu, Alfons Navarro, Anna Gayà, Bernat Gel, Tania Díaz, (unknown), Marı́a Rozman, (unknown), Emili Montserrat, Mariano Monzó	79
17	Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions 2008 ·European Journal of Cancer ·Natalia Ramírez, Eva Bandrés, Alfons Navarro, Aina Pons, (unknown), I. Moreno, F Martínez-Ródenas, Ruth Zárate, Nerea Bitarte, Mariano Monzó, Jesús García‐Foncillas	28
18	Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes XPA, XPD, XPG and ERCC1 in Advanced Colorectal Cancer Patients Treated with First-Line Oxaliplatin/Fluoropyrimidine 2007 ·Oncology ·Mariano Monzó, Isabel Moreno, Alfons Navarro, R. Ibeas, Rosa Artells, Bernat Gel, Francisco Martínez, J.C. Moreno, Raquel Hernández, (unknown)	50
19	Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. 2006 ·PubMed ·Miquel Granell, Álvaro Urbano-Ispizúa, Juan I. Aróstegui, Francesc Fernández‐Avilés, Carmen Martı́nez, Montserrat Rovira, Josefa Rius, Susana Plaza, Anna Gayà, Alfons Navarro, Carme Talarn, Enric Carreras, Mariano Monzó, Emili Montserrat, Jordi Yagüe	51
20	Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. breakdown → 2006 ·Molecular Cancer ·Eva Bandrés, Elena Cubedo, Xabier Agirre, Raquel Malumbres, Ruth Zárate, Natalia Ramírez, (unknown), Alfons Navarro, I. Moreno, Mariano Monzó, Jesús García‐Foncillas	706

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact